Savient Seeks Europe Partner For Gout Drug Krystexxa After CHMP Boost
This article was originally published in The Pink Sheet Daily
Executive Summary
With other companies struggling to develop new gout therapies, Savient is hoping to develop a partnering strategy for Krystexxa in markets outside the U.S. as well as broaden use of the injectable biologic in different categories of patients.
You may also be interested in...
Regeneron Likely Facing New Gout Study Following Arcalyst “Complete Response” Letter
FDA’s decision not to approve rilonacept for preventing gout flares was unsurprising, given its Arthritis Advisory Committee’s unanimous recommendation against the indication. Regeneron says FDA’s letter requests “additional clinical data,” as well as chemistry, manufacturing and controls information.
AstraZeneca’s Ardea Acquisition: A Rich Deal Spurred By Phase III Gout Candidate
The $1.26 billion buyout comes as the pharma is looking to bolt-on acquisitions to help offset recent late-stage pipeline disappointments and sees Ardea’s lesinurad as a potential improvement in gout therapy, an estimated $2 billion global market.
A New Chapter, A New CEO For Dendreon
Former Savient and ImClone CEO Johnson will be responsible for driving commercial expansion of Provenge in the U.S. and Europe. Mitchell Gold steps down as CEO after successfully getting the prostate cancer drug to market following an arduous FDA review but struggling with commercial complexities.